The U.S. House Appropriations Committee is pleased with the U.S. Health Resources and Services Administration (HRSA) for challenging six drug makers’ denials of 340B pricing when covered entities use contract pharmacies, the committee said in a report released yesterday. It encouraged HRSA in the report to fine drug companies, if warranted, for unlawful charges above 340B ceiling prices.
The report accompanies the full committee’s fiscal year 2022 spending bill for the U.S. Labor, Health and Human Services (HHS), and Education departments. The Labor-HHS-Education appropriations subcommittee marked up and passed its version of the bill on Monday. The full committee mark-up began at 10 a.m. Eastern today.
The U.S. House Appropriations Committee is pleased with the U.S. Health Resources and Services Administration (HRSA) for challenging six drug makers’ denials of 340B pricing when covered entities use contract pharmacies, the committee said in a report released yesterday. It encouraged HRSA in the report to fine drug companies, if warranted, for unlawful charges above 340B ceiling prices.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.